One of Roche’s spotlight PhIII cancer drug hopefuls stumbles in a key trial, with hit-and-miss results
Roche’s cancer team at Genentech has turned a few cards on their Phase III prostate cancer study for the AKT blocker ipatasertib, and they’re not …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
